Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492167 | 0.89 | CA1 (0.40) | CA1CA2CA7KDM4EBTN3A1 | |
| Glycerin SCHEMBL25402485 | 0.86 | ALDH1A1 (0.43) | USP2LMNAALDH1A1BTN3A1 | |
| SCHEMBL5487437 | 0.84 | ALOX15 (0.49) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5487441 | 0.84 | ALOX15 (0.49) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16221425 | 0.82 | KMT2A (0.50) | ALDH1A1MEN1KMT2A | |
| SCHEMBL17554321 | 0.82 | KMT2A (0.50) | ALDH1A1MEN1KMT2A | |
| SCHEMBL16221418 | 0.82 | KMT2A (0.50) | ALDH1A1MEN1KMT2A | |
| SCHEMBL17554293 | 0.82 | KMT2A (0.50) | ALDH1A1MEN1KMT2A | |
| SCHEMBL26754534 | 0.81 | CA1 (0.35) | CA1CA2CA7 | |
| SCHEMBL26754532 | 0.81 | TSHR (0.36) | CA1CA2CA7ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114072439-B | Curable composition and resin composition for photofabrication comprising same | 株式会社可乐丽 | 2024-05-14 | — | — | CN | disclosed |
| CN-114981026-A | Metal particle composition, method for producing metal particle composition, and paste | 株式会社可乐丽 | 2022-08-30 | — | — | CN | disclosed |
| CN-114072439-A | Curable composition and resin composition for stereolithography comprising same | 株式会社可乐丽 | 2022-02-18 | — | — | CN | disclosed |
| CN-113661195-A | Polymer, oxygen absorber using the same, and curable composition | 株式会社可乐丽 | 2021-11-16 | — | — | CN | disclosed |
| US-20210163391-A1 | COMPOUND CONTAINING UNSATURATED DOUBLE BOND, OXYGEN ABSORBENT USING SAME AND RESIN COMPOSITION | KURARAY CO., LTD. (JP) | 2021-06-03 | — | — | US | disclosed |
| EP-3782975-A1 | COMPOUND CONTAINING UNSATURATED DOUBLE BOND, OXYGEN ABSORBENT USING SAME AND RESIN COMPOSITION | Kuraray Co., Ltd. (JP) | 2021-02-24 | — | — | EP | disclosed |
| US-20170081690-A1 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-23 | — | — | US | disclosed |
| US-9115358-B2 | Moenomycin biosynthesis-related compositions and methods of use thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-08-25 | — | — | US | disclosed |
| US-20100279980-A1 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOW OF HARWARD COLLEGE | 2010-11-04 | — | — | US | disclosed |
| WO-2008021367-A2 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163391-A1 | COMPOUND CONTAINING UNSATURATED DOUBLE BOND, OXYGEN ABSORBENT USING SAME AND RESIN COMPOSITION | ALOX12, ALOX15B, DUOX2 | USP2 2547/4885CA1 2252/4885CA2 2639/4885 |
| US-20100279980-A1 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | MGAM, GALE, GMDS | USP2 2548/4885CA1 4074/4885CA2 4010/4885 |
| US-20170081690-A1 | MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF | MGAM, GALE, GMDS | USP2 2548/4885CA1 4074/4885CA2 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.